Symbols / JUNS $0.45 -3.57% Jupiter Neurosciences, Inc.
JUNS Chart
About
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Fundamentals
Scroll to Statements| Market Cap | 16.28M | Enterprise Value | 17.81M | Income | -8.64M | Sales | 21.80K | Book/sh | 0.00 | Cash/sh | 0.10 |
| Dividend Yield | — | Payout | 0.00% | Employees | 5 | IPO | — | P/E | — | Forward P/E | 7.48 |
| PEG | — | P/S | 746.73 | P/B | 224.30 | P/C | — | EV/EBITDA | — | EV/Sales | 816.93 |
| Quick Ratio | 0.51 | Current Ratio | 0.65 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -0.25 | EPS next Y | 0.06 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2025-11-14 | ROA | -94.64% | ROE | -7.39% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -128.87% | Profit Margin | 0.00% | Shs Outstand | 36.28M | Shs Float | 18.33M | Short Float | 0.60% |
| Short Ratio | 0.66 | Short Interest | — | 52W High | 3.33 | 52W Low | 0.31 | Beta | — | Avg Volume | 328.27K |
| Volume | 107.48K | Target Price | — | Recom | None | Prev Close | $0.47 | Price | $0.45 | Change | -3.57% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.45
Latest analyst target
3. DCF / Fair value
$-1.15
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.45
Low
—
High
—
Mean
—
- JUNS SEC Filings - JUPITER NEUROSCIENCES, INC. 10-K, 10-Q, 8-K Forms - Stock Titan ue, 31 Mar 2026 18
- How does earnings affect Jupiter Neurosciences (JUNS) Stock | Price at $0.40, Up 4.18% - High Attention Stocks - Cổng thông tin điện tử Tỉnh Sơn La Sat, 04 Apr 2026 07
- JUNS Stock Analysis: Jupiter Neurosciences Inc. Biotech 2.9% Dip Update at $0.37 - UBND thành phố Hải Phòng Fri, 03 Apr 2026 07
- Yorkville defers $6M to 2026 as Jupiter pushes Nugevia sales, Parkinson’s program - Stock Titan Mon, 23 Feb 2026 08
- Jupiter Neurosciences Delays Annual 10-K Filing - TipRanks Wed, 01 Apr 2026 07
- Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance hu, 10 Jul 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Wed, 04 Dec 2024 19
- Jupiter Neurosciences launches support initiative for GLP-1 users - Investing.com Wed, 28 Jan 2026 08
- Jupiter taps pharmacy veterans as Nugevia targets $1.5B market - Stock Titan ue, 07 Apr 2026 07
- Jupiter Neurosciences Receives Nasdaq Deficiency Notices, Faces Delisting - TipRanks Fri, 27 Feb 2026 08
- $50B+ Longevity Opportunity: Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live at Nasdaq - Yahoo Finance Wed, 10 Dec 2025 08
- Latest JUNS News - Jupiter Neurosciences, Inc. to Present at C... - Stock Titan Wed, 03 Dec 2025 08
- Jupiter Neurosciences (NASDAQ: JUNS) files shelf to sell up to $100M in securities - Stock Titan Wed, 15 Apr 2026 23
- Jupiter Neurosciences (NASDAQ: JUNS) wins FDA IND for Phase 2a Parkinson’s trial - Stock Titan Wed, 05 Nov 2025 08
- [NT 10-K] JUPITER NEUROSCIENCES, INC. SEC Filing - Stock Titan Wed, 01 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.02
|
0.00
|
0.00
-100.00%
|
0.23
|
| Operating Revenue |
|
0.02
|
0.00
|
0.00
-100.00%
|
0.23
|
| Cost Of Revenue |
|
0.00
|
—
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
0.00
|
—
|
—
|
—
|
| Gross Profit |
|
0.02
|
—
|
—
|
—
|
| Operating Expense |
|
8.93
+188.76%
|
3.09
-20.14%
|
3.87
+5.59%
|
3.67
|
| Research And Development |
|
2.09
+323.53%
|
0.49
-48.40%
|
0.95
+1.27%
|
0.94
|
| Selling General And Administration |
|
6.84
+163.21%
|
2.60
-10.88%
|
2.92
+7.09%
|
2.72
|
| General And Administrative Expense |
|
6.84
+163.21%
|
2.60
-10.88%
|
2.92
+7.09%
|
2.72
|
| Other Gand A |
|
6.84
+163.21%
|
2.60
-10.88%
|
2.92
+7.09%
|
2.72
|
| Total Expenses |
|
8.93
+188.89%
|
3.09
-20.14%
|
3.87
+5.59%
|
3.67
|
| Operating Income |
|
-8.91
-188.19%
|
-3.09
+20.14%
|
-3.87
-12.77%
|
-3.43
|
| Total Operating Income As Reported |
|
-8.91
-188.19%
|
-3.09
+20.14%
|
-3.87
-12.77%
|
-3.43
|
| EBITDA |
|
-8.58
-291.50%
|
-2.19
+52.00%
|
-4.56
-8.26%
|
-4.22
|
| Normalized EBITDA |
|
-8.58
-186.37%
|
-3.00
+21.70%
|
-3.83
-11.48%
|
-3.43
|
| EBIT |
|
-8.58
-291.50%
|
-2.19
+52.00%
|
-4.56
-8.26%
|
-4.22
|
| Total Unusual Items |
|
0.00
-100.00%
|
0.80
+208.83%
|
-0.74
+5.82%
|
-0.78
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-100.00%
|
0.80
+208.83%
|
-0.74
+5.82%
|
-0.78
|
| Special Income Charges |
|
0.00
-100.00%
|
0.86
+196.60%
|
-0.89
+15.22%
|
-1.05
|
| Other Special Charges |
|
—
|
-0.86
-196.60%
|
0.89
-15.22%
|
1.05
|
| Net Income |
|
-8.64
-254.35%
|
-2.44
+49.00%
|
-4.78
+3.51%
|
-4.96
|
| Pretax Income |
|
-8.64
-254.35%
|
-2.44
+49.00%
|
-4.78
+3.51%
|
-4.96
|
| Net Non Operating Interest Income Expense |
|
-0.07
+72.81%
|
-0.24
-11.27%
|
-0.22
+70.52%
|
-0.74
|
| Interest Expense Non Operating |
|
0.07
-73.42%
|
0.25
+13.56%
|
0.22
-70.48%
|
0.74
|
| Net Interest Income |
|
-0.07
+72.81%
|
-0.24
-11.27%
|
-0.22
+70.52%
|
-0.74
|
| Interest Expense |
|
0.07
-73.42%
|
0.25
+13.56%
|
0.22
-70.48%
|
0.74
|
| Interest Income Non Operating |
|
0.00
-100.00%
|
0.01
+1052.90%
|
0.00
-21.88%
|
0.00
|
| Interest Income |
|
0.00
-100.00%
|
0.01
+1052.90%
|
0.00
-21.88%
|
0.00
|
| Other Income Expense |
|
0.33
-63.12%
|
0.89
+228.76%
|
-0.69
+11.49%
|
-0.78
|
| Other Non Operating Income Expenses |
|
0.33
+266.49%
|
0.09
+102.25%
|
0.04
|
—
|
| Gain On Sale Of Security |
|
—
|
-0.05
-135.80%
|
0.15
-43.34%
|
0.26
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.64
-254.35%
|
-2.44
+49.00%
|
-4.78
+3.51%
|
-4.96
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.64
-254.35%
|
-2.44
+49.00%
|
-4.78
+3.51%
|
-4.96
|
| Net Income From Continuing And Discontinued Operation |
|
-8.64
-254.35%
|
-2.44
+49.00%
|
-4.78
+3.51%
|
-4.96
|
| Net Income Continuous Operations |
|
-8.64
-254.35%
|
-2.44
+49.00%
|
-4.78
+3.51%
|
-4.96
|
| Normalized Income |
|
-8.64
-166.48%
|
-3.24
+19.79%
|
-4.04
+3.07%
|
-4.17
|
| Net Income Common Stockholders |
|
-8.64
-254.35%
|
-2.44
+49.00%
|
-4.78
+3.51%
|
-4.96
|
| Diluted EPS |
|
—
|
-0.08
+55.56%
|
-0.18
-19.37%
|
-0.15
|
| Basic EPS |
|
—
|
-0.08
+55.56%
|
-0.18
-19.37%
|
-0.15
|
| Basic Average Shares |
|
—
|
28.78
+9.01%
|
26.41
-19.68%
|
32.88
|
| Diluted Average Shares |
|
—
|
28.78
+9.01%
|
26.41
-19.68%
|
32.88
|
| Diluted NI Availto Com Stockholders |
|
-8.64
-254.35%
|
-2.44
+49.00%
|
-4.78
+3.51%
|
-4.96
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Assets |
|
5.56
-10.29%
|
6.20
|
—
|
| Current Assets |
|
4.82
+3.76%
|
4.65
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
3.79
+0.53%
|
3.77
|
—
|
| Cash And Cash Equivalents |
|
3.79
+0.53%
|
3.77
|
—
|
| Cash Financial |
|
3.79
+0.53%
|
3.77
|
—
|
| Receivables |
|
0.00
|
0.00
|
0.00
|
| Accounts Receivable |
|
0.00
|
0.00
|
—
|
| Inventory |
|
0.16
|
0.00
|
—
|
| Prepaid Assets |
|
0.77
+0.00%
|
0.77
|
—
|
| Other Current Assets |
|
0.11
-6.61%
|
0.11
|
—
|
| Total Non Current Assets |
|
0.74
-52.39%
|
1.55
|
—
|
| Net PPE |
|
0.02
-66.67%
|
0.07
|
—
|
| Gross PPE |
|
0.24
+0.00%
|
0.24
|
—
|
| Accumulated Depreciation |
|
-0.21
-27.91%
|
-0.17
|
—
|
| Properties |
|
0.00
|
0.00
|
—
|
| Buildings And Improvements |
|
0.24
+0.00%
|
0.24
|
—
|
| Other Properties |
|
—
|
—
|
0.21
|
| Non Current Prepaid Assets |
|
0.71
-51.85%
|
1.48
|
—
|
| Other Non Current Assets |
|
0.00
+0.00%
|
0.00
|
—
|
| Total Liabilities Net Minority Interest |
|
7.40
+264.26%
|
2.03
|
—
|
| Current Liabilities |
|
7.40
+268.11%
|
2.01
|
—
|
| Payables And Accrued Expenses |
|
0.68
+70.67%
|
0.40
|
—
|
| Payables |
|
0.13
-52.95%
|
0.28
|
—
|
| Accounts Payable |
|
0.13
-52.95%
|
0.28
|
—
|
| Current Accrued Expenses |
|
0.55
+360.45%
|
0.12
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.40
-1.25%
|
1.42
|
—
|
| Current Debt And Capital Lease Obligation |
|
5.32
+2606.84%
|
0.20
|
—
|
| Current Debt |
|
5.30
+3518.11%
|
0.15
|
—
|
| Other Current Borrowings |
|
5.30
|
—
|
0.35
|
| Current Capital Lease Obligation |
|
0.02
-57.58%
|
0.05
|
—
|
| Current Deferred Liabilities |
|
0.00
|
0.00
|
—
|
| Current Deferred Revenue |
|
0.00
|
0.00
|
—
|
| Other Current Liabilities |
|
—
|
—
|
0.35
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
0.02
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.02
|
—
|
| Long Term Debt |
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.02
|
—
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
| Stockholders Equity |
|
-1.83
-143.91%
|
4.17
|
—
|
| Common Stock Equity |
|
-1.83
-143.91%
|
4.17
|
—
|
| Capital Stock |
|
0.00
+4.05%
|
0.00
|
—
|
| Common Stock |
|
0.00
+4.05%
|
0.00
|
—
|
| Preferred Stock |
|
0.00
|
0.00
|
—
|
| Share Issued |
|
34.45
+4.06%
|
33.10
+0.01%
|
33.10
|
| Ordinary Shares Number |
|
34.45
+4.06%
|
33.10
+0.01%
|
33.10
|
| Additional Paid In Capital |
|
32.83
+8.75%
|
30.19
|
—
|
| Retained Earnings |
|
-34.67
-33.22%
|
-26.02
|
—
|
| Total Equity Gross Minority Interest |
|
-1.83
-143.91%
|
4.17
|
—
|
| Total Capitalization |
|
-1.83
-143.91%
|
4.17
|
—
|
| Working Capital |
|
-2.57
-197.34%
|
2.64
|
—
|
| Invested Capital |
|
3.47
-19.73%
|
4.32
|
—
|
| Total Debt |
|
5.32
+2342.73%
|
0.22
|
—
|
| Net Debt |
|
1.51
|
—
|
0.11
|
| Capital Lease Obligations |
|
0.02
-70.21%
|
0.07
|
—
|
| Net Tangible Assets |
|
-1.83
-143.91%
|
4.17
|
—
|
| Tangible Book Value |
|
-1.83
-143.91%
|
4.17
|
—
|
| Current Notes Payable |
|
0.00
-100.00%
|
0.15
|
—
|
| Interest Payable |
|
0.04
+3643.33%
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-5.41
-38.42%
|
-3.91
-713.18%
|
-0.48
+61.48%
|
-1.25
|
| Cash Flow From Continuing Operating Activities |
|
-5.41
-38.42%
|
-3.91
-713.18%
|
-0.48
+61.48%
|
-1.25
|
| Net Income From Continuing Operations |
|
-8.64
-254.35%
|
-2.44
+49.00%
|
-4.78
+3.51%
|
-4.96
|
| Other Non Cash Items |
|
0.71
+1121.51%
|
0.06
+246.46%
|
0.02
-97.01%
|
0.56
|
| Stock Based Compensation |
|
2.42
+31.38%
|
1.84
+53.59%
|
1.20
+46.66%
|
0.82
|
| Operating Gains Losses |
|
—
|
-0.80
-208.83%
|
0.74
-5.82%
|
0.78
|
| Gain Loss On Investment Securities |
|
—
|
0.05
+135.80%
|
-0.15
+43.34%
|
-0.26
|
| Change In Working Capital |
|
0.11
+104.11%
|
-2.57
-209.26%
|
2.35
+51.61%
|
1.55
|
| Change In Receivables |
|
-0.00
|
0.00
|
—
|
—
|
| Changes In Account Receivables |
|
-0.00
|
0.00
|
—
|
—
|
| Change In Inventory |
|
-0.16
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
0.00
+100.00%
|
-2.41
-48658.16%
|
0.00
|
—
|
| Change In Payables And Accrued Expense |
|
0.26
+275.33%
|
-0.15
-106.41%
|
2.34
+57.18%
|
1.49
|
| Change In Accrued Expense |
|
0.02
+3725.69%
|
-0.00
-100.03%
|
2.18
+40.81%
|
1.55
|
| Change In Payable |
|
0.24
+261.95%
|
-0.15
-190.69%
|
0.16
+392.97%
|
-0.06
|
| Change In Account Payable |
|
0.24
+261.95%
|
-0.15
-190.69%
|
0.16
+392.97%
|
-0.06
|
| Change In Other Working Capital |
|
0.00
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
0.00
+317.93%
|
-0.00
-7240.00%
|
0.00
-99.96%
|
0.06
|
| Financing Cash Flow |
|
5.43
-28.99%
|
7.65
+1619.56%
|
0.45
-54.70%
|
0.98
|
| Cash Flow From Continuing Financing Activities |
|
5.43
-28.99%
|
7.65
+1619.56%
|
0.45
-54.70%
|
0.98
|
| Net Issuance Payments Of Debt |
|
5.43
+344.41%
|
-2.22
-670.05%
|
0.39
-60.30%
|
0.98
|
| Issuance Of Debt |
|
5.58
+3928.88%
|
0.14
-64.49%
|
0.39
-60.30%
|
0.98
|
| Repayment Of Debt |
|
-0.15
+93.80%
|
-2.36
|
0.00
|
—
|
| Long Term Debt Issuance |
|
5.58
+3928.88%
|
0.14
-64.49%
|
0.39
-60.30%
|
0.98
|
| Long Term Debt Payments |
|
-0.15
+93.80%
|
-2.36
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
5.43
+344.41%
|
-2.22
-670.05%
|
0.39
-60.30%
|
0.98
|
| Short Term Debt Issuance |
|
—
|
—
|
0.39
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.39
|
0.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
9.88
+17854.93%
|
0.06
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
—
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
0.02
-99.47%
|
3.74
+10505.34%
|
-0.04
+86.49%
|
-0.27
|
| Beginning Cash Position |
|
3.77
+13136.57%
|
0.03
-55.80%
|
0.06
-80.51%
|
0.33
|
| End Cash Position |
|
3.79
+0.53%
|
3.77
+13136.57%
|
0.03
-55.80%
|
0.06
|
| Free Cash Flow |
|
-5.41
-38.42%
|
-3.91
-713.18%
|
-0.48
+61.48%
|
-1.25
|
| Interest Paid Supplemental Data |
|
0.04
-74.00%
|
0.15
+425.37%
|
0.03
-65.49%
|
0.08
|
| Income Tax Paid Supplemental Data |
|
—
|
0.00
|
0.00
|
0.00
|
| Change In Interest Payable |
|
0.04
-16.40%
|
0.05
+21.16%
|
0.04
-11.26%
|
0.04
|
| Common Stock Issuance |
|
0.00
-100.00%
|
9.88
+17854.93%
|
0.06
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
9.88
+17854.93%
|
0.06
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-04-01 View
- 8-K2026-02-27 View
- 8-K2026-02-20 View
- 8-K2025-12-23 View
- 8-K2025-12-22 View
- 10-Q2025-11-14 View
- 8-K2025-10-27 View
- 10-Q2025-08-19 View
- 8-K2025-07-10 View
- 8-K2025-07-09 View
- 42025-07-07 View
- 42025-07-07 View
- 42025-07-03 View
- 42025-07-03 View
- 42025-07-01 View
- 42025-07-01 View
- 10-Q2025-05-15 View
- 8-K2025-04-21 View
- 10-K2025-03-28 View
- 8-K2025-03-25 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|